Clinical Trials Directory

Trials / Completed

CompletedNCT04152746

Periostin Levels in Children With Adenoid Hypertrophy

Status
Completed
Phase
Study type
Observational
Enrollment
40 (actual)
Sponsor
Bezmialem Vakif University · Academic / Other
Sex
All
Age
2 Years – 12 Years
Healthy volunteers
Accepted

Summary

Periostin is a matricellular protein that has been shown to be a marker of Type 2 inflammation associated with airway eosinophilia. Matricellular proteins are highly expressed at sites of injury or inflammation. Periostin involves tissue fibrosis and remodeling in the nasal mucosa in some of the otolaryngologic diseases. The up-regulation of periostin expression has been shown in allergic rhinitis, chronic rhinosinusitis with nasal polyps , and aspirin intolerant asthma. In the light of these findings the investigators aimed to evaluate the relation between adenoid hypertrophy and periostin levels.

Detailed description

A total of 40 patients-age ranged between 2 and 12 years- were planned to enroll in the study prospectively. Patients that were scheduled to undergo adenoidectomy were included in the study group (adenoid group). The control group comprised of 20 healthy children who had previously been treated for anemia in the out-patient clinic of the Pediatrics Department and were clinically healthy with normal complete blood cell counts at their follow-up visits. Serum samples were obtained from the two groups. The samples were centrifuged at 1500 g for 5 minute and stored in -80 oC for later analysis of periostin levels. Adenoid tissue and normal mucosal tissue samples were obtained from the adenoidectomy patients and stored in -80 oC for later homogenization and measurement of periostin levels.

Conditions

Interventions

TypeNameDescription
OTHERPeriostin levelThe serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.

Timeline

Start date
2019-10-01
Primary completion
2020-01-10
Completion
2020-02-02
First posted
2019-11-05
Last updated
2020-03-11

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04152746. Inclusion in this directory is not an endorsement.